IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v14y2023i1d10.1038_s41467-023-38218-w.html
   My bibliography  Save this article

N-Formimidoylation/-iminoacetylation modification in aminoglycosides requires FAD-dependent and ligand-protein NOS bridge dual chemistry

Author

Listed:
  • Yung-Lin Wang

    (Academia Sinica)

  • Chin-Yuan Chang

    (National Yang Ming Chiao Tung University)

  • Ning-Shian Hsu

    (Academia Sinica)

  • I-Wen Lo

    (Academia Sinica)

  • Kuan-Hung Lin

    (Academia Sinica)

  • Chun-Liang Chen

    (Academia Sinica)

  • Chi-Fon Chang

    (Academia Sinica)

  • Zhe-Chong Wang

    (Academia Sinica)

  • Yasushi Ogasawara

    (Hokkaido University, Kita-ku)

  • Tohru Dairi

    (Hokkaido University, Kita-ku)

  • Chitose Maruyama

    (Fukui Prefectural University, Eiheiji-cho
    Fukui Prefectural University, Eiheiji-cho)

  • Yoshimitsu Hamano

    (Fukui Prefectural University, Eiheiji-cho
    Fukui Prefectural University, Eiheiji-cho)

  • Tsung-Lin Li

    (Academia Sinica
    National Chung Hsing University)

Abstract

Oxidized cysteine residues are highly reactive and can form functional covalent conjugates, of which the allosteric redox switch formed by the lysine-cysteine NOS bridge is an example. Here, we report a noncanonical FAD-dependent enzyme Orf1 that adds a glycine-derived N-formimidoyl group to glycinothricin to form the antibiotic BD-12. X-ray crystallography was used to investigate this complex enzymatic process, which showed Orf1 has two substrate-binding sites that sit 13.5 Å apart unlike canonical FAD-dependent oxidoreductases. One site could accommodate glycine and the other glycinothricin or glycylthricin. Moreover, an intermediate-enzyme adduct with a NOS-covalent linkage was observed in the later site, where it acts as a two-scissile-bond linkage facilitating nucleophilic addition and cofactor-free decarboxylation. The chain length of nucleophilic acceptors vies with bond cleavage sites at either N–O or O–S accounting for N-formimidoylation or N-iminoacetylation. The resultant product is no longer sensitive to aminoglycoside-modifying enzymes, a strategy that antibiotic-producing species employ to counter drug resistance in competing species.

Suggested Citation

  • Yung-Lin Wang & Chin-Yuan Chang & Ning-Shian Hsu & I-Wen Lo & Kuan-Hung Lin & Chun-Liang Chen & Chi-Fon Chang & Zhe-Chong Wang & Yasushi Ogasawara & Tohru Dairi & Chitose Maruyama & Yoshimitsu Hamano , 2023. "N-Formimidoylation/-iminoacetylation modification in aminoglycosides requires FAD-dependent and ligand-protein NOS bridge dual chemistry," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
  • Handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-38218-w
    DOI: 10.1038/s41467-023-38218-w
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-023-38218-w
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-023-38218-w?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Marie Wensien & Fabian Rabe Pappenheim & Lisa-Marie Funk & Patrick Kloskowski & Ute Curth & Ulf Diederichsen & Jon Uranga & Jin Ye & Pan Fang & Kuan-Ting Pan & Henning Urlaub & Ricardo A. Mata & Vikto, 2021. "A lysine–cysteine redox switch with an NOS bridge regulates enzyme function," Nature, Nature, vol. 593(7859), pages 460-464, May.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Lisa-Marie Funk & Gereon Poschmann & Fabian Rabe von Pappenheim & Ashwin Chari & Kim M. Stegmann & Antje Dickmanns & Marie Wensien & Nora Eulig & Elham Paknia & Gabi Heyne & Elke Penka & Arwen R. Pear, 2024. "Multiple redox switches of the SARS-CoV-2 main protease in vitro provide opportunities for drug design," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    2. Norman Tran & Sathish Dasari & Sarah A. E. Barwell & Matthew J. McLeod & Subha Kalyaanamoorthy & Todd Holyoak & Aravindhan Ganesan, 2023. "The H163A mutation unravels an oxidized conformation of the SARS-CoV-2 main protease," Nature Communications, Nature, vol. 14(1), pages 1-12, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-38218-w. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.